샘플 요청 목록

 카트 문의
시장보고서
상품코드
1752983

세계의 글리코믹스 치료 시장

Glycomic Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 401 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

글리코믹스 치료 세계 시장, 2030년에는 3,957억 달러에 도달에

2024년에 1,627억 달러로 추정되는 글리코믹스 치료 세계 시장은 2024-2030년 CAGR 16.0%로 성장하여 2030년에는 3,957억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 Isolated Class는 CAGR 17.5%를 나타내고, 분석 기간 종료시에는 2,787억 달러에 이를 것으로 예측됩니다. Synthetic Class 부문의 성장률은 분석 기간중 CAGR 12.9%로 추정됩니다.

미국 시장은 443억 달러로 추정, 중국은 CAGR 21.4%로 성장 예측

미국의 글리코믹스 치료 시장은 2024년에 443억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 874억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 21.4%로 예측됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 11.6%와 14.4%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 12.7%로 추정됩니다.

세계의 '글리코믹스 치료' 시장 - 주요 동향과 촉진요인 정리

왜 '글리코믹스 치료'가 정밀의료의 새로운 개척지로 떠오르는가?

글리코믹스 치료는 세포 신호전달, 면역, 질병 진행에 관여하는 당쇄(복합당질)를 표적으로 삼아 조작하는 것으로, 생물의학 분야의 최첨단을 달리고 있습니다. 당쇄는 염증, 종양 증식, 병원체 인식, 면역 조절 등의 과정에서 중요한 역할을 합니다. 기존의 저분자 화합물이나 유전자 치료와 달리 글리코믹스는 암, 자가면역질환, 감염성 질환 등 복잡한 질환의 진단, 모니터링, 치료에 활용할 수 있는 완전히 새로운 생물학적 지식을 제공합니다. 제약업계가 개인화 및 시스템 수준의 접근 방식으로 전환하는 가운데, 당쇄 구조를 분석하고 표적화하는 능력은 기존의 분자 표적을 넘어서는 새로운 고선택적 치료법의 문을 열어줄 수 있습니다. 글리코믹스 치료는 정밀의료의 잠재력을 극대화하기 위한 다음 단계로 점점 더 많은 관심을 받고 있습니다.

어떤 과학기술의 발전이 당쇄 기반 의약품 개발을 가능하게 하는가?

분석화학, 당쇄공학, 바이오인포매틱스의 비약적인 발전은 글리코믹스 치료의 실용화에 매우 중요한 역할을 하고 있습니다. 고급 질량 분석과 고처리량 당쇄 프로파일링을 통해 연구자들은 전례 없는 깊이와 속도로 당쇄 구조를 특성화할 수 있게 되었습니다. 글리코엔지니어링 기술을 통해 당단백질을 변형하여 치료 효과를 높이고, 면역원성을 낮추거나, 약물의 반감기를 연장하는 등 다양한 치료법을 개발할 수 있게 되었습니다. 또한, CRISPR 및 기타 유전자 편집 도구는 당단백질 생산을 제어하기 위해 인공 세포주에서 당쇄 형성 경로를 제어하기 위해 사용되고 있습니다. 글리코믹, 프로테옴, 유전체 데이터를 통합하는 바이오인포매틱스 플랫폼은 연구자들이 질병에 특화된 당쇄 시그니처를 식별하는 데 도움을 주고 있으며, 이는 더 나은 약물 타겟팅과 바이오마커 탐색으로 이어지고 있습니다. 이러한 기술적 시너지 효과로 인해 글리코믹스는 학문적 영역에서 상업적으로 추진되는 치료 분야로 빠르게 변모하고 있습니다.

전 세계적으로 임상 적용 및 치료 파이프라인은 어떻게 발전하고 있는가?

현재 글리코믹스 치료는 여러 치료 분야, 특히 종양학, 면역학, 바이러스학에 진출해 있습니다. 시알산 리간드나 당쇄 의존성 면역 체크포인트와 같이 종양 세포의 비정상적인 당쇄 발현을 표적으로 하는 암 면역치료가 활발히 연구되고 있습니다. 희귀 유전성 질환 분야에서는 당쇄 발현을 최적화한 효소 보충 요법이 치료 성적을 향상시키고 있습니다. 각 기업들은 또한 바이러스 스파이크 단백질의 당쇄 차폐를 표적으로 하는 코로나19 후보물질 등 당쇄 기반 항바이러스제 및 백신 개발도 진행하고 있습니다. 당쇄를 통한 세포 접착과 신호전달이 면역세포의 거동에 중요한 역할을 하기 때문에 염증성 질환과 자가면역질환도 중요한 초점이 되고 있습니다. 연구 자금과 바이오 의약품 투자 측면에서는 현재 북미가 선두를 달리고 있지만, 유럽의 연구기관과 스타트업도 적극적으로 참여하고 있습니다. 아시아태평양, 특히 일본과 한국은 글리칸 과학과 치료제 개발의 중요한 혁신 허브로 부상하고 있습니다.

글리코믹스 치료 시장 성장 촉진요인과 과제는?

글리코믹 치료제 시장의 성장은 정밀치료에 대한 수요 증가, 글리코믹 생물학에 대한 이해의 확대, 신규 생물학적 제제에 대한 투자 증가에 기인합니다. 제약사들은 치료 포트폴리오를 다양화하고 새로운 작용기전으로 미충족 의료 수요를 충족시키기 위해 이 분야에 투자하고 있습니다. 정부의 연구비 지원과 민관 공동 연구도 기초적인 당쇄 연구를 임상 파이프라인으로 끌어올리는 데 기여하고 있습니다. 하지만, 당쇄 구조의 복잡성, 표준화된 분석 플랫폼의 부족, 제한된 상업적 선례, 높은 연구개발비용 등의 과제도 남아있습니다. 또한, 당쇄 의약품을 기반으로 한 약물에 대한 규제의 길은 아직 개발 중이며, 이로 인해 승인이 지연될 수 있습니다. 이러한 장애물에도 불구하고, 이 분야는 큰 잠재력을 가지고 있습니다. 과학적 이해가 진전되고 상업적 경로가 성숙해짐에 따라 글리코믹스 치료는 미래 의약품 개발의 기초가 될 것으로 기대됩니다.

부문

클래스(분리 클래스, 합성 클래스); 구조(당단백질 구조, 시알산 구조 표적, 프로테오글리칸 구조, 당사미노글리칸 구조 표적, 고정 단백질 및 헤파린 기반 글리칸 구조, 당지질 구조 표적, 기타 구조); 적응증(혈전증 및 화학적 예방 적응증, 빈혈 적응증, 백내장 적응증, 고셔병 적응증, MPS-1 및 IV 적응증, 암 적응증, 알츠하이머병 적응증, 기타 적응증)

조사 대상 기업 예(총 44개사)

  • Acuitas Therapeutics
  • Agilent Technologies Inc.
  • Alzheon Inc.
  • AMS Bio
  • Arrakis Therapeutics
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Bio-Techne Corporation
  • Bruker Corporation
  • F. Hoffmann-La Roche Ltd.
  • Genovis AB
  • GlaxoSmithKline plc
  • GlycoMar Limited
  • Grifols S.A.
  • Halozyme Therapeutics Inc.
  • ICON plc
  • Intellihep Ltd.
  • Ludger Ltd.
  • Merck KGaA
  • New England Biolabs Inc.
  • Protalix Biotherapeutics Inc.
  • RayBiotech Life Inc.
  • Sanofi S.A.
  • Shimadzu Corporation
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Vector Laboratories
  • Waters Corporation
  • Z Biotech LLC
  • Zymeworks Inc.

AI 통합

우리는 유효한 전문가 컨텐츠와 AI툴로 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.06.26

Global Glycomic Therapeutics Market to Reach US$395.7 Billion by 2030

The global market for Glycomic Therapeutics estimated at US$162.7 Billion in the year 2024, is expected to reach US$395.7 Billion by 2030, growing at a CAGR of 16.0% over the analysis period 2024-2030. Isolated Class, one of the segments analyzed in the report, is expected to record a 17.5% CAGR and reach US$278.7 Billion by the end of the analysis period. Growth in the Synthetic Class segment is estimated at 12.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$44.3 Billion While China is Forecast to Grow at 21.4% CAGR

The Glycomic Therapeutics market in the U.S. is estimated at US$44.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$87.4 Billion by the year 2030 trailing a CAGR of 21.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.6% and 14.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.7% CAGR.

Global "Glycomic Therapeutics" Market - Key Trends & Drivers Summarized

Why Are Glycomic Therapeutics Emerging as a Frontier in Precision Medicine?

Glycomic therapeutics-targeting and manipulating glycans (complex sugars) involved in cell signaling, immunity, and disease progression-represent a cutting-edge frontier in biomedical science. Glycans play vital roles in processes such as inflammation, tumor growth, pathogen recognition, and immune modulation. Unlike traditional small molecules or even genetic therapies, glycomics offers an entirely new layer of biological insight that can be used to diagnose, monitor, and treat complex diseases, including cancer, autoimmune disorders, and infectious diseases. As the pharmaceutical industry shifts toward personalized and systems-level approaches, the ability to analyze and target glycan structures opens the door to novel, highly selective therapies that go beyond conventional molecular targets. Glycomic therapeutics are increasingly viewed as the next step in unlocking precision medicine’s full potential.

What Scientific and Technological Advancements Are Enabling Glycan-Based Drug Development?

Breakthroughs in analytical chemistry, glycoengineering, and bioinformatics have been critical in making glycomic therapeutics commercially viable. Advanced mass spectrometry and high-throughput glycan profiling now allow researchers to characterize glycan structures at unprecedented depth and speed. Glycoengineering techniques enable the modification of glycoproteins to enhance therapeutic efficacy, reduce immunogenicity, or prolong drug half-life-capabilities especially valuable in biologics such as monoclonal antibodies. Furthermore, CRISPR and other gene editing tools are being used to regulate glycosylation pathways in engineered cell lines for controlled glycoprotein production. Bioinformatics platforms integrating glycomic, proteomic, and genomic data are helping researchers identify disease-specific glycan signatures, leading to better drug targeting and biomarker discovery. These technological synergies are rapidly transforming glycomics from an academic discipline into a commercially driven therapeutic space.

How Are Clinical Applications and Therapeutic Pipelines Evolving Globally?

Currently, glycomic therapeutics are making inroads across multiple therapeutic areas, particularly oncology, immunology, and virology. Cancer immunotherapies targeting abnormal glycan expressions on tumor cells-such as sialic acid ligands or glycan-dependent immune checkpoints-are under active investigation. In the field of rare genetic diseases, enzyme replacement therapies with optimized glycosylation are improving treatment outcomes. Companies are also developing glycan-based antivirals and vaccines, including COVID-19 candidates that target glycan shields on viral spike proteins. Inflammatory and autoimmune conditions are another key focus, as glycan-mediated cell adhesion and signaling play crucial roles in immune cell behavior. North America currently leads in terms of research funding and biopharmaceutical investment, but European institutions and startups are also active players. Asia-Pacific, particularly Japan and South Korea, is emerging as a significant innovation hub for glycan science and therapeutic development.

What Are the Key Market Drivers and Challenges for Glycomic Therapeutics?

The growth in the glycomic therapeutics market is driven by rising demand for precision treatments, expanding understanding of glycan biology, and increasing investment in novel biologics. Pharmaceutical companies are investing in this space to diversify their therapeutic portfolios and to address unmet medical needs with new mechanisms of action. Government research funding and public-private collaborations are also propelling foundational glycomics research into clinical pipelines. However, challenges remain-including the complexity of glycan structures, lack of standardized analytical platforms, limited commercial precedents, and high R&D costs. Additionally, regulatory pathways for glycomic-based drugs are still evolving, which can slow down approvals. Despite these obstacles, the field holds vast potential. As scientific clarity improves and commercial pathways mature, glycomic therapeutics are expected to become a foundational component of future drug development.

SCOPE OF STUDY:

The report analyzes the Glycomic Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Class (Isolated Class, Synthetic Class); Structure (Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure, Other Structures); Indication (Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication, Other Indications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Acuitas Therapeutics
  • Agilent Technologies Inc.
  • Alzheon Inc.
  • AMS Bio
  • Arrakis Therapeutics
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Bio-Techne Corporation
  • Bruker Corporation
  • F. Hoffmann-La Roche Ltd.
  • Genovis AB
  • GlaxoSmithKline plc
  • GlycoMar Limited
  • Grifols S.A.
  • Halozyme Therapeutics Inc.
  • ICON plc
  • Intellihep Ltd.
  • Ludger Ltd.
  • Merck KGaA
  • New England Biolabs Inc.
  • Protalix Biotherapeutics Inc.
  • RayBiotech Life Inc.
  • Sanofi S.A.
  • Shimadzu Corporation
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Vector Laboratories
  • Waters Corporation
  • Z Biotech LLC
  • Zymeworks Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Glycomic Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advancements in Glycobiology Research Throw Spotlight on Novel Therapeutic Applications
    • Rising Focus on Personalized Medicine and Biomarker Discovery Drives Demand for Glycan-Based Drugs
    • Integration of Glycomics with Immunotherapy Strengthens Business Case in Oncology and Autoimmune Disorders
    • Expansion of Biopharmaceutical Pipelines Accelerates Investment in Glyco-Engineering Technologies
    • Strategic Collaborations Between Academia and Biotech Fuel Innovation in Glycomics Research
    • Growing Applications in Vaccine Design and Infectious Disease Modulation Generate Market Interest
    • Use of AI in Glycan Mapping Enhances Precision in Drug Development and Disease Profiling
    • Emerging Role of Glycans in Neurological Disorders Expands Targeted R&D Investment
    • Supportive Regulatory Pathways for Rare and Orphan Drugs Accelerate Clinical Trials in Glycomic Therapies
    • Global Genomic and Proteomic Initiatives Drive Integration of Glycomic Data for RWE
    • Scalability Challenges and Complex Manufacturing Present Bottlenecks in Commercialization
    • Licensing and IP Portfolios Create Competitive Advantages for Early Glycomic Innovators
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Glycomic Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Glycomic Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Glycomic Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Glycomic Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Isolated Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Isolated Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Isolated Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Synthetic Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Synthetic Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Synthetic Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Thrombosis & Chemoprophylaxis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Thrombosis & Chemoprophylaxis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Thrombosis & Chemoprophylaxis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Anemia Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Anemia Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Anemia Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Cataract Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Cataract Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Cataract Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Gaucher's Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Gaucher's Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Gaucher's Disease Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for MPS-1 & IV Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for MPS-1 & IV Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for MPS-1 & IV Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Cancer Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Alzheimer's Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Alzheimer's Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Alzheimer's Disease Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Glycoproteins Structure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Glycoproteins Structure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Glycoproteins Structure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Targeting Sialic Acid Structure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Targeting Sialic Acid Structure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Targeting Sialic Acid Structure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Proteoglycans Structure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Proteoglycans Structure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: World 16-Year Perspective for Proteoglycans Structure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Targeting Glycosaminoglycans Structure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Targeting Glycosaminoglycans Structure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: World 16-Year Perspective for Targeting Glycosaminoglycans Structure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Anchored Proteins & Heparin Based Glycans Structure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Anchored Proteins & Heparin Based Glycans Structure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: World 16-Year Perspective for Anchored Proteins & Heparin Based Glycans Structure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Targeting Glycosphingolipids Structure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Targeting Glycosphingolipids Structure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: World 16-Year Perspective for Targeting Glycosphingolipids Structure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Other Structures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Other Structures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: World 16-Year Perspective for Other Structures by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Glycomic Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 56: USA Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: USA 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: USA 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: USA 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Canada 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Canada 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Canada 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • JAPAN
    • Glycomic Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Japan 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Japan 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Japan 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • CHINA
    • Glycomic Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 83: China Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: China 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: China 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: China 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • EUROPE
    • Glycomic Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Glycomic Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Glycomic Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Europe 16-Year Perspective for Glycomic Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Europe 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Europe 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Europe 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • FRANCE
    • Glycomic Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 104: France Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: France Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: France 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 107: France Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: France 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: France 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • GERMANY
    • Glycomic Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 113: Germany Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Germany 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Germany 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Germany 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 122: Italy Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Italy Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Italy 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 125: Italy Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Italy Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Italy 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 128: Italy Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Italy 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Glycomic Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 131: UK Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: UK Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: UK 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 134: UK Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: UK Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: UK 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 137: UK Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: UK Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: UK 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 140: Spain Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Spain Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Spain 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 143: Spain Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Spain Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Spain 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 146: Spain Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Spain Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Spain 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 149: Russia Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Russia Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Russia 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 152: Russia Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Russia Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Russia 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 155: Russia Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Russia Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Russia 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Europe Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Europe 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Europe Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Europe 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Europe Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Europe 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Glycomic Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Glycomic Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Asia-Pacific Historic Review for Glycomic Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Asia-Pacific 16-Year Perspective for Glycomic Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Asia-Pacific Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Asia-Pacific 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Asia-Pacific Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Asia-Pacific 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Asia-Pacific Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Asia-Pacific 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Glycomic Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 179: Australia Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Australia Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Australia 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 182: Australia Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Australia Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Australia 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 185: Australia Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Australia Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Australia 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • INDIA
    • Glycomic Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 188: India Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: India Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: India 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 191: India Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: India Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: India 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 194: India Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: India Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: India 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 197: South Korea Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: South Korea Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: South Korea 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 200: South Korea Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: South Korea Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: South Korea 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 203: South Korea Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: South Korea Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: South Korea 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Asia-Pacific Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Asia-Pacific 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 209: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Asia-Pacific Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Rest of Asia-Pacific 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 212: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Rest of Asia-Pacific Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Rest of Asia-Pacific 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Glycomic Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 215: Latin America Recent Past, Current & Future Analysis for Glycomic Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 216: Latin America Historic Review for Glycomic Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Latin America 16-Year Perspective for Glycomic Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 218: Latin America Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Latin America Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Latin America 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 221: Latin America Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Latin America Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Latin America 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 224: Latin America Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Latin America Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Latin America 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 227: Argentina Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Argentina Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Argentina 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 230: Argentina Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Argentina Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Argentina 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 233: Argentina Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Argentina Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Argentina 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 236: Brazil Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Brazil Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Brazil 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 239: Brazil Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Brazil Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Brazil 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 242: Brazil Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Brazil Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Brazil 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 245: Mexico Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Mexico Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Mexico 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 248: Mexico Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Mexico Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Mexico 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 251: Mexico Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Mexico Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Mexico 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Rest of Latin America Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Rest of Latin America 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 257: Rest of Latin America Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Rest of Latin America Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Rest of Latin America 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 260: Rest of Latin America Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Rest of Latin America Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Rest of Latin America 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Glycomic Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 263: Middle East Recent Past, Current & Future Analysis for Glycomic Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 264: Middle East Historic Review for Glycomic Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Middle East 16-Year Perspective for Glycomic Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 266: Middle East Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Middle East Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Middle East 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 269: Middle East Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Middle East Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Middle East 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 272: Middle East Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Middle East Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Middle East 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 275: Iran Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Iran Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Iran 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 278: Iran Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Iran Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: Iran 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 281: Iran Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Iran Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: Iran 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 284: Israel Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Israel Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: Israel 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 287: Israel Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Israel Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: Israel 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 290: Israel Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Israel Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: Israel 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Saudi Arabia Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: Saudi Arabia 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 296: Saudi Arabia Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Saudi Arabia Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Saudi Arabia 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 299: Saudi Arabia Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Saudi Arabia Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Saudi Arabia 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 302: UAE Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: UAE Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: UAE 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 305: UAE Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: UAE Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 307: UAE 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 308: UAE Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: UAE Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 310: UAE 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Middle East Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 313: Rest of Middle East 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 314: Rest of Middle East Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Middle East Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 316: Rest of Middle East 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 317: Rest of Middle East Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Rest of Middle East Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 319: Rest of Middle East 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030
  • AFRICA
    • Glycomic Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 320: Africa Recent Past, Current & Future Analysis for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Africa Historic Review for Glycomic Therapeutics by Class - Isolated Class and Synthetic Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 322: Africa 16-Year Perspective for Glycomic Therapeutics by Class - Percentage Breakdown of Value Sales for Isolated Class and Synthetic Class for the Years 2014, 2025 & 2030
    • TABLE 323: Africa Recent Past, Current & Future Analysis for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Africa Historic Review for Glycomic Therapeutics by Indication - Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 325: Africa 16-Year Perspective for Glycomic Therapeutics by Indication - Percentage Breakdown of Value Sales for Thrombosis & Chemoprophylaxis Indication, Anemia Indication, Cataract Indication, Gaucher's Disease Indication, MPS-1 & IV Indication, Cancer Indication, Alzheimer's Disease Indication and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 326: Africa Recent Past, Current & Future Analysis for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Africa Historic Review for Glycomic Therapeutics by Structure - Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 328: Africa 16-Year Perspective for Glycomic Therapeutics by Structure - Percentage Breakdown of Value Sales for Glycoproteins Structure, Targeting Sialic Acid Structure, Proteoglycans Structure, Targeting Glycosaminoglycans Structure, Anchored Proteins & Heparin Based Glycans Structure, Targeting Glycosphingolipids Structure and Other Structures for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제